BioLineRx Investor Relations Material
Latest events
Q2 2024
BioLineRx
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from BioLineRx Ltd
Access all reports
BioLineRx Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for oncology and rare diseases. The company's primary product pipeline includes therapies aimed at treating multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors. BioLineRx leverages extensive drug development expertise to advance these therapies from preclinical stages through to commercialization. The company is headquartered in Hevel Modi'in, Israel, and its shares are listed on the NASDAQ.
Latest articles
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
BLRX
Country
🇺🇸 United States